Mid Pharmaceuticals

Abbott India Ltd.

ABBOTINDIA

₹31575.0

-0.19% (-60.0)

Market Cap

₹66,883 Cr.

P/E

47.29

Abbott India Ltd.

Price
Growth Table
Balance Sheet
Profit & Loss
Cash Flow
Cash Flow Analysis
Ratios
Quarterly Results
Reverse DCF

FAQs on Abbott India Ltd. Shareprice

Has the share price of Abbott India grown faster than its competition?

Abbott India has given lower returns compared to its competitors.
Abbott India has grown at ~20.02% over the last 2yrs while peers have grown at a median rate of 38.54%

Is Abbott India stock expensive?

Abbott India is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Abbott India is 47.51, while 3 year average PE is 49.94.
Also latest EV/EBITDA of Abbott India is 38.69 while 3yr average is 36.83.

View FAQ's On Business

Growth Table

Abbott India Ltd.
Aurobindo Pharma
Loading...
Alkem Laboratories
Loading...

In %	1yr	2yr	3yr	4yr	5yr	6yr	7yr	8yr	9yr	10yr
Share Price CAGR	14.57	19.38	20.82	17.93	14.44	24.19	25.46	28.33	24.35	23.36
TTM EPS CAGR	17.56	21.00	21.11	19.17	18.87	21.00	19.44	22.45	20.96	20.05
Sales CAGR	9.58	9.47	9.22	10.43	9.38	9.69	9.91	10.24	10.33	10.85
PAT Margin (Abs Growth)	2.58	3.99	4.42	5.39	7.63	7.74	10.46	10.23	9.99	11.28
PE CAGR	-2.54	-1.34	-0.24	-1.04	-3.73	2.64	5.04	4.80	2.80	2.76
CFO CAGR	35.75	13.13	18.61	17.97	19.43	41.25	21.67	21.90	21.21	22.82

* Share price and PE growth are updated everyday. All other fields are as of latest financial year end. EPS adjusted for bonus and splits.

Balance Sheet

Abbott India Ltd.
Aurobindo Pharma
Loading...
Alkem Laboratories
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Assets	1,607	2,053	2,402	2,928	3,532	3,823	4,207	4,539	5,178	5,917
Non Current Assets	166	173	151	180	342	353	371	1,530	1,948	1,152
Net Block	108	110	81.38	105	270	251	271	237	225	140
Capital Work in Progress	2.83	6.28	2.17	0.73	1.64	0.66	0.66	3.66	10.11	18.08
Intangible Assets Under Development	0.93	1.13	—	—	—	—	—	—	—	—
Long Term Investments	—	—	—	—	—	—	—	—	—	—
Current Assets	1,451	1,893	2,231	2,761	3,205	3,487	3,853	3,025	3,246	4,742
Inventory	370	501	585	607	527	718	688	649	620	882
Accounts Receivable	145	176	263	276	318	250	288	319	319	380
Short Term Investments	—	—	—	—	—	—	—	—	—	—
Cash & Bank Balances	839	1,091	1,031	1,684	2,197	2,409	2,749	1,937	2,134	1,628
Liabilities	1,607	2,053	2,402	2,928	3,532	3,823	4,207	4,539	5,178	5,917
Shareholders Funds	1,196	1,387	1,693	2,009	2,432	2,602	2,820	3,189	3,699	4,233
Share Capital	21.25	21.25	21.25	21.25	21.25	21.25	21.25	21.25	21.25	21.25
Reserves	1,174	1,352	1,651	1,960	2,375	2,537	2,754	3,125	3,637	4,212
Non Current Liabilities	29.25	34.84	40.75	62.36	210	190	184	144	136	277
Secured Loans	—	—	—	—	—	—	—	—	—	—
Unsecured Loans	—	—	—	—	—	—	—	—	—	—
Current Liabilities	382	632	668	857	891	1,031	1,203	1,206	1,343	1,407
Accounts Payable	230	475	481	664	658	763	889	892	1,003	1,058
Short Term Loans	—	—	—	—	—	—	—	—	—	—

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

Increase
Decrease
Total

No data available.

*Data is as of latest FY end

Profit & Loss

Abbott India Ltd.
Aurobindo Pharma
Loading...
Alkem Laboratories
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Sales	2,615	2,903	3,299	3,679	4,093	4,310	4,913	5,349	5,849	6,409
Operating Expenses	2,251	2,508	2,775	3,075	3,337	3,391	3,832	4,143	4,396	4,715
Raw Material	313	316	296	406	452	454	495	559	566	621
Bottles	13.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Chemicals	266	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Others	26.75	316	296	406	452	454	495	559	566	—
Packaging Films	6.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Material Cost (%)	57.16	59.08	57.62	56.78	56.57	55.47	54.08	55.62	55.06	6.87
Employee Cost	341	345	394	436	476	493	579	564	577	588
Power & Fuel Cost	6.98	7.74	10.26	12.61	13.73	12.74	14.98	17.15	16.63	—
Operating Profit	364	395	523	604	756	919	1,082	1,205	1,453	1,695
Other Income	51.24	60.15	118	114	115	83.47	83.35	154	248	276
OPM (%)	13.91	13.60	15.87	16.42	18.47	21.32	22.01	22.54	24.84	26.44
Depreciation and Amortisation	14.44	16.43	16.19	16.92	59.61	58.13	66.10	69.97	71.17	71.80
Interest	2.52	2.04	3.82	2.25	8.53	18.28	19.10	15.99	12.45	11.43
Profit Before Tax	398	436	621	699	803	926	1,080	1,274	1,618	1,887
Tax	143	160	220	249	210	235	281	324	417	473
Net Profit	255	277	401	450	593	691	799	949	1,201	1,414
Number of shares(Crs)	2.12	2.12	2.12	2.12	2.12	2.12	2.12	2.12	2.12	—
Dividend Payout Ratio(%)	29.14	30.72	29.13	30.67	89.60	84.61	73.17	72.74	72.53	—

TTM Values as of Mar 2025

Cash Flow

Abbott India Ltd.
Aurobindo Pharma
Loading...
Alkem Laboratories
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash from Operating Activity	249	307	153	499	626	727	948	893	1,213	1,012
Profit Before Tax	398	436	621	699	803	926	1,080	1,274	1,618	1,887
Adjustments	-23.98	-37.02	-76.92	-77.46	-17.22	24.99	23.30	-62.70	-130	-165
OCF Before Working Capital	374	399	545	621	785	951	1,103	1,211	1,488	1,722
Working Capital Changes	21.85	66.52	-187	134	69.82	11.26	134	23.13	129	-263
Taxes Paid	-147	-159	-205	-257	-229	-235	-289	-341	-404	-447
Cash from Investing Activity	-77.19	-155	-215	-257	-401	-71.82	-396	-148	-416	182
Net Fixed Assets Purchased	-22.66	-21.37	27.33	4.46	-15.57	-23.18	-43.84	-33.63	-48.13	-52.08
Fixed Assets Purchased	-22.72	-21.51	-24.26	-12.49	-15.74	-23.31	-44.07	-34.11	-48.33	-52.60
Fixed Assets Sold	0.06	0.14	51.59	16.95	0.17	0.13	0.23	0.48	0.20	0.52
Investment Purchased	-105	-189	-105	-554	-506	-135	-2,650	-5,455	-4,641	—
Investment Sold	—	—	—	—	—	—	2,229	5,239	4,129	—
Interest Recieved	50.04	55.32	62.96	92.63	120	86.48	68.99	102	144	125
Dividends Recieved	—	—	—	—	—	—	—	—	—	—
Subsidiary Investments	—	—	—	—	—	—	—	—	—	—
Cash from Financing Activity	-80.29	-89.76	-102	-143	-217	-582	-637	-639	-745	-925
Proceeds From Shares	—	—	—	—	—	—	—	—	—	—
Net Long Term Borrowings	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Proceeds From Borrowings	—	—	—	—	—	—	—	—	—	—
Repayment From Borrowings	—	—	—	—	—	—	—	—	—	—
Interest Paid	-1.01	-0.25	-0.13	-1.90	-0.23	-0.51	-0.70	-0.49	-0.20	—
Dividend Paid	-65.87	-74.37	-85.00	-117	-138	-531	-584	-584	-691	-871
Net Cash Flow	91.19	62.05	-165	99.33	8.13	73.13	-85.56	107	52.07	269
Opening Cash & Cash Equivalents	49.00	140	202	37.68	137	145	218	133	240	292
Effect of FX	—	—	—	—	—	—	—	—	—	—
Closing Cash & Cash Equivalents	140	202	37.68	137	145	218	133	240	292	561
Net Capex (est)	22.66	21.37	-27.33	-4.46	15.57	23.18	43.84	33.63	48.13	52.08
Free Cash Flow (est)	226	286	180	504	611	704	904	860	1,165	960

Cash Flow Analysis

Increase
Decrease
Total

No data available.

Ratios

= Dominant Factor

Abbott India Ltd.
Aurobindo Pharma
Loading...
Alkem Laboratories
Loading...

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Operational Ratios
Quick Ratio	1.53	2.83	2.20	2.46	2.51	3.00	2.69	2.63	1.97	1.96
Liquid Assets (Crs)	1,279	1,081	1,392	1,646	2,154	2,677	2,770	3,165	2,376	2,626
Current Liabilities (Crs)	834	382	632	668	857	891	1,031	1,203	1,206	1,343
Current Ratio	1.99	3.79	3.00	3.34	3.22	3.60	3.38	3.20	2.51	2.42
Current Assets (Crs)	1,663	1,451	1,893	2,231	2,761	3,205	3,487	3,853	3,025	3,246
Current Liabilities (Crs)	834	382	632	668	857	891	1,031	1,203	1,206	1,343
Interest Coverage Ratio	685	159	215	164	312	95.10	51.65	57.53	80.66	131
EBIT (Crs)	345	401	439	625	701	811	944	1,099	1,290	1,630
Interest Expenses (Crs)	0.50	2.52	2.04	3.82	2.25	8.53	18.28	19.10	15.99	12.45
Fixed Asset Turnover	10.62	21.29	20.78	26.55	22.36	11.87	12.65	11.54	14.58	13.78
Net Sales (Crs)	2,289	2,615	2,903	3,299	3,679	4,093	4,310	4,913	5,349	5,849
Fixed Assets (Crs)	216	123	140	124	165	345	341	426	367	425
Cash Conversion Cycle	31.52	19.20	-0.98	-7.55	-14.06	-27.09	-34.41	-42.91	-44.66	-49.80
Inventory Days	58.54	52.03	54.07	59.93	59.14	50.56	50.82	51.02	44.44	38.30
Days Receivable	18.77	18.91	19.95	24.26	26.77	26.49	23.19	19.54	20.18	19.26
Days Payable	45.79	51.74	75.01	91.74	99.97	104	108	113	109	107
Debt to Equity Ratio	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Debt (Crs)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Shareholders Equity (Crs)	938	1,196	1,387	1,693	2,009	2,432	2,602	2,820	3,189	3,699
Free Cash Flow/Sales (%)	8.70	8.64	9.85	5.46	13.69	14.92	16.32	18.40	16.07	19.91
Free Cash Flow(est) (Crs)	199	226	286	180	504	611	704	904	860	1,165
Net Sales (Crs)	2,289	2,615	2,903	3,299	3,679	4,093	4,310	4,913	5,349	5,849
Profitability Ratios
Gross Margin (%)	42.58	42.84	40.92	42.38	43.22	43.43	44.53	45.92	44.38	44.94
Op Profit Margin (%)	13.60	13.91	13.60	15.87	16.42	18.47	21.32	22.01	22.54	24.84
Operating Profit (Crs)	360	415	455	641	718	871	1,002	1,165	1,360	1,701
Net Sales (Crs)	2,289	2,615	2,903	3,299	3,679	4,093	4,310	4,913	5,349	5,849
Net Profit Margin (%)	10.00	9.76	9.53	12.16	12.24	14.49	16.03	16.26	17.75	20.54
Net Profit (Crs)	229	255	277	401	450	593	691	799	949	1,201
Net Sales (Crs)	2,289	2,615	2,903	3,299	3,679	4,093	4,310	4,913	5,349	5,849
ROCE (%)	25.17	32.70	30.84	36.07	33.85	30.71	33.82	36.58	38.70	42.51
EBIT (Crs)	345	401	439	625	701	811	944	1,099	1,290	1,630
Capital Employed (Crs)	1,370	1,225	1,422	1,734	2,071	2,641	2,792	3,004	3,333	3,835
Return on Assets (%)	10.39	15.88	13.47	16.71	15.38	16.79	18.07	18.98	20.92	23.20
Net Profit (Crs)	229	255	277	401	450	593	691	799	949	1,201
Total Assets (Crs)	2,204	1,607	2,053	2,402	2,928	3,532	3,823	4,207	4,539	5,178
ROIC (%)	68.55	65.32	82.89	52.91	115	131	211	428	65.22	63.33
Op Profit after Taxes (Crs)	197	224	240	327	378	515	642	751	846	1,026
Invested Capital (Crs)	287	343	289	619	330	393	304	175	1,298	1,620
ROE (%)	24.42	21.35	19.95	23.70	22.42	24.38	26.54	28.32	29.78	32.48
Net Profit Margin (%)	10.00	9.76	9.53	12.16	12.24	14.49	16.03	16.26	17.75	20.54
Asset Turnover ratio	1.04	1.63	1.41	1.37	1.26	1.16	1.13	1.17	1.18	1.13
Equity Multiplier	2.35	1.34	1.48	1.42	1.46	1.45	1.47	1.49	1.42	1.40
Adjusted EPS	108	120	130	189	212	279	325	376	447	565
Valuation Ratios
P/E	36.64	39.19	35.63	28.86	34.43	55.39	46.11	47.09	49.43	47.67
Price to Book	8.95	8.37	7.18	6.93	7.83	13.71	12.45	13.55	14.92	15.65
EV/EBITDA	21.53	22.08	19.27	16.44	19.25	35.19	29.37	29.93	33.09	32.40
Dividend Yield (%)	0.79	0.74	0.86	1.01	0.89	1.62	1.83	1.55	1.47	1.52

Quarterly Results

Abbott India Ltd.
Aurobindo Pharma
Loading...
Alkem Laboratories
Loading...

In Rs. Cr.	Mar'20	Mar'21
Net Sales	961	1,096
Operating Expenses	823	890
Increase/Decrease in Stock	-69.92	-41.92
Raw Material	139	107
Employee Cost	116	121
Selling and Distribution Expenses	0.00	0.00
Electricity, Power & Fuel Cost	0.00	0.00
Gen_AdminExpenses	0.00	0.00
Miscellaneous Expenses	0.00	0.00
Operating Profit	138	206
Other Income	28.13	16.20
Interest	2.82	4.74
PBDT	164	217
Depreciation and Amortization	14.81	15.11
Profit Before Tax	149	202
Tax	37.96	49.41
Profit After Tax	111	152
Exceptional Items	0.00	0.00
Net Profit	111	152
Quarterly Ratios
EPS	52.22	71.75
Operating Profit Margin	14.40	18.76
Net Profit Margin	11.54	13.92

Reverse DCF

Earnings

Discount Rate (%)

Terminal Multiple

5 YEAR

10 YEAR

20 YEAR

54.10%

Implied Growth Rate over a 5 year period*

20.00%

Implied Growth Rate over a 10 year period*

9.00%

Implied Growth Rate over a 20 year period*

*Implied Growth calculated using Newton-Rhapson method.

Learn how to use Reverse DCF

FAQs on Abbott India Ltd. Financials

How strong is Abbott India balance sheet?

Balance sheet of Abbott India is strong.
It shouldn't have solvency or liquidity issues.

Is the debt of Abbott India increasing or decreasing?

Yes, The net debt of Abbott India is increasing.
Latest net debt of Abbott India is -₹1,627.92 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹4,268.98 Crs.

Is the profitablity of Abbott India improving?

Yes, profit is increasing.
The profit of Abbott India is ₹1,414 Crs for TTM, ₹1,201 Crs for Mar 2024 and ₹949 Crs for Mar 2023.

Does Abbott India pay decent dividends?

The company seems to pay a good stable dividend.
Abbott India latest dividend payout ratio is 72.53% and 3yr average dividend payout ratio is 72.81%

How has Abbott India allocated its funds?

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Abbott India Ltd.

Abbott India Ltd.

Has the share price of Abbott India grown faster than its competition?

Is Abbott India stock expensive?

How strong is Abbott India balance sheet?

Is the debt of Abbott India increasing or decreasing?

Is the profitablity of Abbott India improving?

Does Abbott India pay decent dividends?

How has Abbott India allocated its funds?

SIGN UP FOR FREE